Relay Therapeutics (RLAY) Change in Accured Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Change in Accured Expenses data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 1290.26% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 74.25% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 114.87% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.7 million, up from -$615000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for RLAY reached as high as $17.9 million in Q3 2022 and fell as low as -$19.5 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $798411.8 across 5 years, with a median of $469000.0 in 2025.
• Across the five-year window, Change in Accured Expenses slumped 310.53% in 2022 and jumped 1290.26% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at -$16.7 million in 2022, then soared by 135.01% to $5.8 million in 2023, then sank by 224.94% to -$7.3 million in 2024, then surged by 91.57% to -$615000.0 in 2025, then soared by 696.1% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $3.7 million in Q1 2026, -$615000.0 in Q4 2025, and $469000.0 in Q3 2025.